| Identification | |
| Name: | Benzoicacid, 2-[(2,3-dimethylphenyl)amino]- |
| Synonyms: | Anthranilicacid, N-2,3-xylyl- (8CI); 2-(2,3-Dimethylanilino)benzoic acid;2-[(2,3-Dimethylphenyl)amino]benzoic acid; 2',3'-Dimethyl-N-phenylanthranilicacid; Bafameritin M; Baphameritin M; Bonabol; C.I. 473; CN 35355; Coslan; INF3355; In-M; Lysalgo; Mefacit; Mefenacid; Mefenamic acid; Mephenamic acid;N-(2,3-Dimethylphenyl)anthranilic acid; N-(2,3-Xylyl)-2-aminobenzoic acid;N-(2,3-Xylyl)anthranilic acid; NSC 94437; Namphen; Parkemed; Ponalar; Ponstan;Ponstel; Ponstil; Ponstyl; Pontal; Relafan; Tanston; Vialidon |
| CAS: | 61-68-7 |
| EINECS: | 200-513-1 |
| Molecular Formula: | C15H15 N O2 |
| Molecular Weight: | 241.2851 |
| InChI: | InChI=1S/C15H15NO2/c1-10-6-5-9-13(11(10)2)16-14-8-4-3-7-12(14)15(17)18/h3-9,16H,1-2H3,(H,17,18) |
| Molecular Structure: |  |
| Properties | |
| Density: | 1.203 g/cm3 |
| Refractive index: | 1.639 |
| Water Solubility: | insoluble |
| Solubility: | insoluble |
| Appearance: | light yellow solid |
| Specification: |
?Mefenamic acid , its cas register number is 61-68-7. It also can be called?Mefenamic acid [USAN:INN:BAN:JAN] ; 2-((2,3-Dimethylphenyl)amino)benzoic acid ; 2-Diphenylaminecarboxylic acid, 2',3'-dimethyl- ; Ac. mefenamico ; Ac. mefenamico [Italian] ; Acide mefenamique ; Acide mefenamique [French] ; Acide mefenamique [INN-French] ; Acido mefenamico ; Acido mefenamico [INN-Spanish] ; Acidum mefenamicum ; Acidum mefenamicum [INN-Latin] ; Anthranilic acid, N-2,3-xylyl- ; Bafhameritin-M ; Benzoic acid, 2-((2,3-dimethylphenyl)amino)- ; Benzoic acid, 2-(2,3-dimethylphenyl)amino- ; Bonabol ; Fenamin ; HL 1 ; Lysalgo ; Mefacit ; Mefedolo ; Mefenamate ; Mefenamic acid ; Mefenaminsaeure ; Mephenamic acid ; Mephenaminic acid ; Methenamic acid ; Mycasaal ; N-(2,3-Dimethylphenyl)anthranilic acid ; N-(2,3-Xylyl)-2-aminobenzoic acid ; N-2,3-Xylylanthranilic acid ; Namphen ; Parkemed ; Ponalar ; Ponstan ; Ponstan forte ; Ponstel ; Rolan ; Tamany Bonsan ; Tanston ; Vialidon . It is a?light yellow solid. Since?it plays a significant role in mefenamic acid elimination, patients with known liver deficiency may be prescribed lower doses. Kidney deficiency may also cause accumulation of the drug and its metabolites in the excretory system. Therefore patients suffering from renal conditions should not be prescribed mefenamic acid. |
| Storage Temperature: | Refrigerator |
| Color: | CRYSTALS WHITE TO OFF-WHITE, CRYSTALLINE POWDER |
| Usage: | Anti-inflammatory; analgesic. |
| Safety Data | |
| Hazard Symbols |
Xn:Harmful
|
 |
|
